ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Service: Trial Number:
Principal Investigator: Conducted at:
Miller Children`s & Women`s Hospital Long Beach
Currently enrolling additional patients:
Age Range:
6 months to less than 18 years of age
Male & Female

Primary Mediastinal Large B-Cell Lymphoma (PMBCL) is an uncommon type of non Hodgkin’s lymphoma in children. PMBCL is more difficult to cure in children than other types of B cell lymphomas. Recent studies in adults have shown very promising results with the combination of a drug called rituximab with a chemotherapy regimen known as DA-EPOCH. Using rituximab with DA-EPOCH has not been studied in the children or adolescents. This study is being done to find out what effects (good and/or bad) using rituximab in combination with the DA-EPOCH chemotherapy regimen will have on children with PMLBL. We also want to find out if this new approach can improve the treatment success of children with PMLBL.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
The email to associate with this registration.